An Imaging Study to Investigate the Distribution of GW842166X in the Brain.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-26

Study Completion Date

2007-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GW842166X is being developed for the treatment and management of inflammatory pain. GW842166X is a CB2 receptor agonist and the mechanism is not fully understood, although it is thought that for the anti-inflammatory action the drug is required to cross inot the brain from the blood. This study aims to look at if the drug crosses into the brain once given orally using an imaging technique called positron emission tomography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants

NCT04911543

Healthy

COMPLETED PHASE1

PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram

NCT00250172

Dosimetry Healthy

COMPLETED PHASE1

Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients

NCT03977012

Complex Regional Pain Syndromes

UNKNOWN

Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112

NCT00088517

Healthy

COMPLETED PHASE1

The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials

NCT01546155

Healthy Controls

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Inflammatory

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects receiving GW842166

Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive \[carbonyl-\^11C\]GW842166.

Group Type EXPERIMENTAL

GW842166X

Intervention Type DRUG

GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.

[carbonyl-^11C]GW842166

Intervention Type DRUG

\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GW842166X

GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.

Intervention Type DRUG

[carbonyl-^11C]GW842166

\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male aged 50 to 80yrs inclusive at the screening visit.
* subjects with negative HIV and hepatitis B and C test results within 3 months of study start.

Exclusion Criteria

* A negative Allens test on arm to be used for arterial cannulation.
* Any contraindications to MRI scanning.
* History or presence of hepatic or renal disease.
* Previous involvement in PET or radiological investigations.
* Family history of cancer.
* History of claustrophobia
* Presence of a cardiac pacemaker or any other electronic device or ferromagnetic metal

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes